If Japan is to become a front-runner in pharmaceutical development, it must not only speed up its approval of new drugs, but also enhance its own research capabilities, argue Kaori Tsuji and Kiichiro Tsutani.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McCurry, J. Lancet 369, 1333–1336 (2007).
Fukuhara, H. Iyakusangyoseisaku Kenkyujo (Office of Pharmaceutical Industry Research, Research Paper No. 31, 2006) [in Japanese].
Tsuji, K. & Tsutani, K. Jpn. J. Clin. Pharmacol. Therapeut. 38, S198 (2007) [in Japanese].
Tsuji, K. & Tsutani, K. Eur. J. Pharm. Biopharm. 68, 496–502 (2008).
Author information
Authors and Affiliations
Additional information
Kaori Tsuji consults for RHC USA Corporation, a US-based drug distributor in Japan. See Editorial, page 823 , and online at http://tinyurl.com/3tt3y3 .
Rights and permissions
About this article
Cite this article
Tsuji, K., Tsutani, K. Follow the leader. Nature 453, 851–852 (2008). https://doi.org/10.1038/453851a
Published:
Issue Date:
DOI: https://doi.org/10.1038/453851a
This article is cited by
-
Oncology drug lag in Japan: has it improved over the last decade?
International Journal of Clinical Oncology (2023)
-
Analysis of Pediatric Drug Approval Lag in Japan
Therapeutic Innovation & Regulatory Science (2021)
-
Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
International Journal of Clinical Oncology (2015)
-
Investigator-initiated cancer trials with INDs for approval in Japan
Nature Reviews Clinical Oncology (2010)
